Skip to main content

Humanigen, Inc

HGENDelisted Oct 12, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001293310

Humanigen, Inc was delisted on Oct 12, 2023; its insiders filed their last Form 4 on Oct 20, 2023; 38 institutions reported holding it in 13F filings for Q2 2023, worth $839.7K in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 12:44 PM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2022: $70.7M (2813.4% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Humanigen, Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Feb 28, 2022–––
Revenue$2.51M$3.60M$312.0K––
Operating expenses$70.8M$236.4M$88.5M$8.94M$11.3M
Research and development$55.2M$213.1M$72.7M$2.62M$2.22M
Selling, general and administrative$15.6M$23.3M$15.8M$6.33M$9.11M
Operating income-$68.3M-$232.8M-$88.2M-$8.94M-$11.3M
Interest expense$2.92M$2.26M$1.34M$1.35M$852.0K
Income tax–$21.6M–––
Net income-$70.7M-$236.6M-$89.5M-$10.3M-$12.0M
EPS, basic$-0.79––––
EPS, diluted$-0.79––––
Weighted shares, basic89.2M––––
Weighted shares, diluted89.2M––––
Margins and growth
Operating margin-2716.9%-6474.9%-28268.6%––
Net margin-2813.4%-6582.7%-28697.1%––
Revenue growth, year over year−30.1%+1,052.2%–––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Humanigen, Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Feb 28, 2022–––
Cash and equivalents$10.2M$70.0M$67.7M$143.0K$814.0K
Total current assets$11.1M$71.0M$68.2M$452.0K$1.30M
Total assets$11.2M$71.1M$68.3M$523.0K$1.37M
Accounts payable$40.5M$44.7M$13.1M$5.05M$2.86M
Total current liabilities$56.2M$68.7M$20.4M$13.6M$8.26M
Long-term debt–$25.0M–$6.49M–
Total liabilities$58.0M$94.7M$22.8M$14.8M$9.48M
Shareholders' equity-$46.8M-$23.7M$45.5M-$14.3M-$8.11M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Humanigen, Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endDec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018
Filing10-K10-K10-K10-K10-K
Reported–Feb 28, 2022–––
Operating cash flow-$76.7M-$184.0M-$69.9M-$4.00M-$6.21M
Depreciation and amortization––––$19.0K
Stock-based compensation$5.81M$5.37M$2.11M$2.02M$4.81M
Investing cash flow––-$20.0K––
Financing cash flow$16.8M$186.3M$137.5M$3.33M$6.26M
Net change in cash–$2.28M$67.6M-$671.0K$47.0K
Ratio
Stock-based compensation, % of revenue231.1%149.3%676.3%––

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Humanigen, Inc by cover date
Cover dateShares outstandingChange in a yearFiling
May 3, 2023119.1M+68.6%SEC
Mar 16, 2023119.1M+82.3%SEC
Nov 9, 2022119.1M+86.6%SEC
Aug 9, 2022103.7M+74.5%SEC
May 2, 202270.6M+19.5%SEC
Feb 16, 202265.3M+22.2%SEC
Nov 9, 202163.8M+23.6%SEC
Aug 5, 202159.4M−71.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.